Henry Schein, Inc. (HSIC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive sentiment with strong financial performance, strategic growth initiatives, and stable market conditions. Despite some uncertainties in guidance, the company shows solid growth in key segments, optimistic future earnings, and market share gains. The involvement of KKR and the stabilization of margins further support a positive outlook. The Q&A session highlighted management's confidence in continued growth and strategic advancements, although some specifics were withheld. Overall, the positive aspects outweigh the uncertainties, suggesting a positive stock price movement in the near term.
Key Financial Performance
Global sales $3.3 billion with sales growth of 5.2% compared to the third quarter of 2024, reflecting constant currency sales growth of 4.0% and a 1.2% increase resulting from foreign currency exchange. Acquisitions contributed 0.7% sales growth to the quarter.
GAAP operating margin 4.88%, a decrease of 6 basis points compared to the prior year GAAP operating margin.
Non-GAAP operating margin 7.83%, an increase of 19 basis points compared to the prior year non-GAAP operating margin. Improvement driven by lower operating expenses as a percentage of sales, partially offset by lower gross margin.
Gross margin Down 56 basis points year-over-year, primarily related to product mix in the Global Distribution Group and Global Specialty Products segment. Sequentially declined due to seasonality of flu vaccine sales in the medical business.
Effective tax rate (non-GAAP) 22.9% for the third quarter of 2025, lower than the 24.9% in the third quarter of 2024. The decrease reflects the nontaxable nature of the remeasurement gain recognized in the quarter.
GAAP net income $101 million or $0.84 per diluted share, compared to $99 million or $0.78 per diluted share in the prior year.
Non-GAAP net income $167 million or $1.38 per diluted share, compared to $155 million or $1.22 per diluted share in the prior year. Foreign currency exchange favorably impacted diluted EPS by approximately $0.01.
Adjusted EBITDA $295 million, representing growth of 10% compared to $268 million in the third quarter of 2024.
Global Distribution and Value-Added Services Group sales Grew by 4.8%. U.S. dental merchandise sales grew 3.3%, U.S. dental equipment sales grew 1.2% with strong growth in digital equipment. U.S. medical distribution sales grew 4.7% despite lower demand for influenza vaccines and respiratory diagnostic products. Home Solutions business grew over 20% on an as-reported basis and 6% excluding acquisitions. International dental merchandise sales grew 6.0% or 2.5% in constant currency. International dental equipment sales grew 10.1% or 5.7% in constant currency.
Global Specialty Products Group sales Grew 5.9% or 3.9% in constant currency. Implant and biomaterial business experienced solid growth, including double-digit growth in value implants and low single-digit growth in premium implants. High single-digit sales growth in Europe, including low double-digit growth in Germany.
Global Technology Group sales Grew 9.7% or 9.0% in constant currency. U.S. sales growth driven by practice management software with double-digit growth in Dentrix Ascend and solid growth in revenue cycle management business. Internationally, sales growth driven by double-digit growth in Dentally cloud-based practice management solutions products.
Operating cash flow $174 million in the third quarter of 2025, compared to $151 million in the third quarter of 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HenrySchein.com Global eCommerce Platform: Successfully launched in the U.K. and Ireland, with a phased rollout planned for North America and Europe in 2026.
Digital Equipment: Achieved double-digit growth in U.S. dental equipment sales, driven by strong volume growth despite lower average selling prices.
BioHorizons Tapered Pro Conical implant: Now represents approximately 1/3 of U.S. implant sales, with positive customer feedback and ongoing growth.
AI Integration with Dentrix Ascend and Dentally: Partnership with Amazon Web Services to integrate generative AI technology, enhancing real-time documentation, voice-activated charting, and predictive business intelligence.
Market Share Gains: Achieved solid market share gains in U.S. distribution businesses, driven by promotional programs and corporate brand sales.
International Implant Sales: High single-digit growth in international implant sales, particularly in the DACH region and Latin America.
BOLD+1 Strategy: Focused on high-growth, high-margin businesses, aiming for over 50% of non-GAAP operating income from these areas by 2027.
Value Creation Initiatives: Targeting over $200 million in operating income improvements through centralization, procurement, automation, and corporate brand sales.
Restructuring Program: Expected to achieve annual run-rate savings of over $100 million, with extended restructuring charges into 2026 and 2027.
KKR Partnership: Amendment to strategic partnership agreement allows KKR to increase stock ownership up to 19.9%.
Share Repurchase Program: Board approved a $750 million increase, with plans to continue buybacks at a similar pace.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cyber Incident: The company faced a significant cyber incident in October 2023, which disrupted operations and caused some customers to delay their return. Although the issue is stated to be resolved, it highlights vulnerabilities to cybersecurity threats.
Lower Average Selling Price in Digital Equipment: The company is experiencing a lower average selling price in digital equipment, which could impact revenue despite strong volume growth.
Decline in Traditional Equipment Sales: Traditional equipment sales have declined slightly, attributed to the timing of installations, which could affect short-term revenue.
Lower Demand for Respiratory Diagnostic Products and Influenza Vaccines: The U.S. Medical business faced lower demand for respiratory diagnostic products and influenza vaccines, partially offsetting growth in other areas.
Gross Margin Decline: Gross margin decreased by 56 basis points year-over-year, primarily due to product mix in the Global Distribution Group and Global Specialty Products segment.
Restructuring Costs: The company is extending its restructuring plan into 2026 and 2027, which will incur additional restructuring charges, potentially impacting short-term financial performance.
Economic Sensitivity in Implant Sales: U.S. implant and biomaterials sales grew modestly due to a challenging prior-year comparison, indicating sensitivity to economic conditions.
Regulatory and Market Risks in International Expansion: The company’s international expansion, including the European rollout of its eCommerce platform, involves navigating new markets, regulations, and cultural differences, which could pose challenges.
Supply Chain and Seasonal Risks: Gross margins were affected by the seasonality of flu vaccine sales and supply chain dynamics, which could continue to impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Operating Income Improvement: The company expects to deliver over $200 million of improvements to operating income over the next few years through multiyear projects focused on centralization of support services, indirect procurement, automating and simplifying processes, and accelerating sales of corporate brand products.
Earnings Growth: The company aims to return to its long-term goal of high single-digit to low double-digit earnings growth.
Non-GAAP Operating Income: The company remains on track to achieve its goal of over 50% of non-GAAP operating income coming from high-growth, high-margin businesses by the end of 2027, with more than 10% coming from corporate brands.
Share Repurchase Program: The Board approved a $750 million increase in the share repurchase program, with expectations to continue buybacks at a similar pace to the past quarter.
Global eCommerce Platform Rollout: The phased launch of the new HenrySchein.com Global eCommerce Platform in North America is underway, with a European rollout expected in 2026.
U.S. Equipment Sales: The company expects to maintain overall U.S. equipment growth in the fourth quarter, supported by a good order intake at DS World.
Implant and Biomaterials Growth: Growth in implant and biomaterials products is expected to continue, driven by strong performance in the Tapered Pro Conical implant and SmartShape Healers abutment products.
Cloud-Based Practice Management Solutions: The company anticipates continued growth in its cloud-based platforms, including Dentrix Ascend and Dentally, which have seen a 20% year-over-year increase in customers.
AI Integration in Technology Group: The company expects its partnership with Amazon Web Services to integrate generative AI technology into its platforms to drive incremental revenue and greater productivity for customers.
2025 Financial Guidance: Non-GAAP diluted EPS is expected to be in the range of $4.88 to $4.96 per share, with 2025 sales growth projected at 3% to 4% over 2024. Adjusted EBITDA is expected to grow in the mid-single digits.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Our Board recently approved a $750 million increase in this program, and our current expectation is to continue to execute buybacks at a similar pace to the past quarter.
Share Repurchase Details: During the third quarter of 2025, the company repurchased approximately 3.3 million shares of common stock at an average price of $68.62 per share for a total of $229 million. At the end of the quarter, Henry Schein had $980 million authorized and available for future share repurchases, which includes $750 million that the Board of Directors authorized in September.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's outlook on future earnings growth and the $200 million EBIT benefit?
A:The company is optimistic about future earnings growth, with the $200 million EBIT benefit being a significant contributor. They expect some operating improvements in 2026 and will provide more detailed guidance in February.
Q:What factors contributed to the midpoint of 2025 EPS guidance increasing by $0.05?
A:The increase was partly due to a remeasurement gain and the momentum in sales growth. The company achieved 4.5% operating income growth year-over-year, excluding certain gains, and is confident in the momentum going into the fourth quarter.
Q:How is the company performing in terms of market share and pricing stability?
A:The company is gaining market share in areas like implants, endodontics, and medical products. Pricing has stabilized, with minimal inflation and stable glove pricing. The company is also benefiting from its own brands and value-added services.
Q:What is the outlook for gross margins in the distribution business?
A:Gross margins in the U.S. dental business have stabilized due to stable glove pricing and normalized promotional activity. Medical margins were affected by product mix, but sales growth in pharmaceuticals and other products is expected to continue.
Q:What is driving the performance of the Specialty Products Group?
A:The Specialty Products Group saw growth in value implants but lower margins compared to premium implants. Endodontic sales remain steady, and operational changes in orthodontics are expected to contribute to growth in 2026.
Q:What is the company's plan for the $200 million operating income improvement?
A:The $200 million improvement is a net figure, inclusive of reinvestments. The plan will be phased over multiple years, with more details on 2026 benefits to be provided in future guidance.
Q:What is the company's relationship with KKR, and how does it impact strategy?
A:KKR has increased its stake in the company to 19.9%. They have provided input on best practices and value creation initiatives, and their involvement has been positive, with active participation from their board members.
Q:What is the status of the Heartland relationship and tariff impacts?
A:The company did not provide specific details about the Heartland relationship but emphasized strong DSO relationships and supply chain solutions. Tariff impacts have been managed through local sourcing and negotiations, with minimal inflation effects.
Q:What are the company's assumptions for share gains in merchandise and equipment?
A:The company is confident in its market share gains, driven by promotional activities and strong sales momentum. Specific assumptions for 2026 will be provided in future guidance.
Q:What is the company's overall outlook and strategy moving forward?
A:The company is optimistic about its future, with strong management, motivated teams, and strategic initiatives like the BOLD+1 plan and value creation program. They aim to simplify operations, manage margins, and continue advancing the business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the Heartland relationship, assumptions for share gains in 2026, and the exact phasing of the $200 million EBIT benefit. They also did not commit to specific numbers for 2026 guidance, citing the need for further assessment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI technology
Ascend cycle
BOLD
Dentally
Sales digit
Stanley
UK
biomaterials endodontics
buyback pace
cycle solution
demand product
expectation buyback
gain sale
gain tax
group sale
improvement income
influenza vaccine
offering
point margin
practice solution
process
product sale
program restructuring
purchase
restructuring program
result gain
return term
sale currency
sale equipment
sale margin
sale segment
sale service
search
service group
share market
tool
vaccine sale
value creation
HSIC Transcript
Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral5-27
Henry Schein, Inc. (HSIC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call revealed mixed signals: strong revenue and EPS growth, but a slight decline in operating margin and free cash flow. The lack of strategic or operational updates, along with the absence of guidance, tempers enthusiasm. With no market cap information and a typical reaction to mixed results, the stock price is likely to remain stable, leading to a neutral prediction.
Henry Schein, Inc. (HSIC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
HSIC Slides
HSIC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
